Nigeria Receives First Lenacapavir Shipment to Boost HIV Prevention Efforts
The Federal Government of Nigeria has officially taken delivery of the first consignment of lenacapavir injection doses, a groundbreaking long-acting HIV prevention medication, aimed at significantly strengthening the country's efforts to combat the spread of HIV. This pivotal shipment, received on Wednesday at the Federal Central Stores in Oshodi, Lagos, represents a major milestone in a comprehensive Global Fund-supported initiative designed to enhance public health outcomes across the nation.
Details of the Shipment and Distribution Plan
Speaking at the formal handover ceremony, Mohammed Patiko, the Head of Procurement and Supply Chain Management at the National AIDS and STIs Control Programme (NASCP), confirmed that this initial tranche consists of 11,520 doses. He elaborated that Nigeria is set to receive a total of 52,000 doses of lenacapavir, which will be delivered in three separate batches. The remaining doses are scheduled for arrival in May and October of this year, ensuring a steady supply to support ongoing prevention activities.
Patiko emphasized that the lenacapavir injection is a preventive intervention specifically engineered to drastically reduce the risk of HIV infection among vulnerable populations. The programme is strategically targeted at high-risk groups, including serodiscordant couples, key populations such as men who have sex with men (MSM), female sex workers (FSW), and transgender persons, as well as individuals with elevated vulnerability to HIV exposure due to various socio-economic factors.
Implementation and Accessibility
In a significant move to ensure broad access, Patiko announced that the injections will be administered free of charge to all enrolled participants as part of a national pilot and research programme. The rollout will be conducted through designated health facilities across eight pilot states, which have been carefully selected for this initiative. These states include Kwara, Gombe, Ebonyi, Anambra, the Federal Capital Territory (FCT), Akwa Ibom, Cross River, and Benue.
"These are the Global Fund-supported states, and the lenacapavir injections will be available at designated secondary health facilities in these regions," Patiko stated. He further noted that distribution is expected to commence next week, utilizing existing logistics systems to ensure efficient and timely delivery to the points of care.
Advancements in HIV Prevention
Lenacapavir represents a significant advancement in HIV prevention strategies, offering extended protection compared to traditional daily oral pre-exposure prophylaxis (PrEP). This long-acting injectable drug simplifies prevention for users, potentially improving adherence and effectiveness in reducing new infections.
Also speaking at the event, Oladipupo Fisher, the Lagos State AIDS Programme Coordinator, described this development as a major boost to Nigeria's HIV response strategy. "Nigeria is firmly on track to eliminate HIV/AIDS by 2030," Fisher asserted. "These innovative prevention products are absolutely crucial to achieving our global targets. They will play a vital role in reducing new infections and contributing to epidemic control by the end of this decade."
Comprehensive Strategy for Epidemic Control
Fisher underscored that while prevention remains a key pillar of the strategy, scaling up testing and treatment is equally important in reducing transmission rates. "For those already infected with HIV, effective treatment reduces viral load, making transmission less likely. Therefore, increased testing and treatment enrollment remain central strategies in our comprehensive approach," he added, highlighting the multifaceted nature of Nigeria's public health response.
Nigeria continues to face a significant HIV burden, with health authorities consistently working to address the challenges posed by the epidemic. The introduction of innovative prevention tools like lenacapavir is viewed as critical to accelerating progress toward the ambitious goal of ending the HIV epidemic by 2030. This initiative not only showcases Nigeria's commitment to public health but also aligns with global efforts to leverage scientific advancements for better health outcomes.
